CARA News and Press, Cara Therapeutics Inc. From 01/15/20

Today, we will be studying why Trevi Therapeutics ( TRVI ) is an attractive investment for 2020. Company overview Trevi Therapeutics is a clinical-stage company focused on the development of nalbuphine ER to treat multiple serious and chronic neurologically mediated conditions . Nalbuph...

Today, we will be studying why Cara Therapeutics ( CARA ) is an attractive investment for 2020. Company overview Cara Therapeutics is a clinical-stage company focused on the development of peripheral KORs (kappa opioid receptors). The company’s lead investigational product and fir...

STAMFORD, Conn., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today anno...

It's not necessarily their intent, but when most investors begin their hunt for a new stock pick, it starts and ends with a large-cap name (a stock with a market capitalization of $10 billion to $200 billion). They're simply easier to find, to the point where investors often just stumble acros...

Choosing between a stock that has a lot of upside and one that offers stability can be a difficult decision for investors, and it could make a significant impact on overall returns. Cara Therapeutics (NASDAQ: CARA) and Fresenius Medical Care AG & Co. (NYSE: FMS) are two companies tha...

As exciting as 2019 was for biotech investors , this upcoming year is gearing up to be possibly even more interesting, with many potential blockbuster drugs on the horizon. A number of these candidates have come from small-cap biotech companies with the chance of making big gains if they receiv...

While small-cap stocks -- those with market caps between $500 million and $2 billion -- don't get as much attention as their large-cap cousins, there are plenty of promising investments in this area. Given their smaller sizer, these stocks have much more growth potential and are capable of multi...

Cara Therapeutics ( CARA ) recently reported the top-line results of its phase II clinical study of oral KORSUVA in patients with CKD-associated pruritus. Following the positive phase II clinical trial results, the stock price plunged for almost 35% on December 3, 2019. Our investment thesis i...

Before we ring in 2020, December will be ripe for swings in biotech stock prices. 2019 started strong, waned, and then regained momentum amid a slew of successful clinical trial results, several acquisition announcements, and positive drug approval decisions that came often months ahead of the U...

STAMFORD, Conn., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced t...